In conclusion, examining the PI3K/Akt/mTOR pathway within an integrated immuno-metabolic-signal framework for IR/MASH-driven HCC not only deepens our understanding of the pathophysiology of this important HCC subtype but also provides a critical theoretical basis and a fresh perspective for overcoming current therapeutic dilemmas. This evidence concerns the gene MTOR and hepatocellular carcinoma.